Skip to main content

Advertisement

Table 3 Baseline (t0) features and JC viruria of 21 MS, 18 CIRDs and 22 CD patients

From: Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study

Pathology Cohort1 MS Cohort2 Cohort3 CD Control group
PsA RA AS CIRDs
Female / Male 10 / 11* 5 / 6 8 / 0 2 / 1 15 / 7 8 / 10 10 / 9
JCPyV+ / JCPyV- 2 / 18* 4 / 7 7 /1 3 / 0 14 / 8 6 / 12 5 / 14
JCPyV load 3.90 (3.70 - 4.10) 7.27 (4.23-8.09) 6.92 (4.15-8.13) 7.25 (5.08-7.68) 7.21 (4.15 - 8.13) 6.30 (4.85-8.85) 5.75 (3.54-8.43)
Age 37 (19–49) 53 (46–72) 53.5 (36–79) 47 (38–54) 53 (36–79) 15 (8–22) 35 (25–47)
Symptoms onset, months ago 72 (12–300) 60 (24–312) 108 (52–156) 120 (36–420) 75 (24–420) nd  
Disease activity†§ 2 (0–4)§ 4.11 (2.46–4.61)§ 4.18 (2.50–5,89)§ 7,3 (4–10)§   > 30 §  
  1. MS: multiple sclerosis; PsA: psoriatic arthritis; RA: rheumatoid arthritis; AS: ankylosing spondylitis; CD: Crohn's disease; CIRDs: chronic inflammatory rheumatic diseases.
  2. † For each category the median values (range) are indicated. In particular JCPyV loads values are expressed as log10 genome equivalent (gEq)/mL in urine and in plasma, and as log10 gEq/106 cells in PBMCs.
  3. §: Disease Activity is indicated by scale, score or index specific for each disease assessed: for Cohort1 MS, Kurtzke Expanded Disability Status Scale (EDSS) is used. This scale ranges from 0 (normal neurological examination) to 10 (confined to bed); for PsA and RA (Cohort2), Disease Activity Score with a 28-joint count related to C-reactive protein (DAS28-CRP) is used, with a high score indicating more active disease; for AS (Cohort2), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is used. This index ranges from 0 (no activity) to 10 (maximum activity); for Cohort3 CD, Pediatric Crohn's Disease Activity Index (PCDAI) is used (score ≤10: inactive disease; 10–30: mild disease; >30: moderate to severe disease).
  4. * At t0, 1 patient (out of the 21 multiple sclerosis patients enrolled) do not perform the urine and blood sampling.
  5. ‡ nd: no data.